Literature DB >> 9176535

Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).

A Guhlmann1, M Storck, J Kotzerke, F Moog, L Sunder-Plassmann, S N Reske.   

Abstract

BACKGROUND: A study was undertaken to investigate the accuracy of positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) in the thoracic lymph node staging of non-small cell lung cancer (NSCLC).
METHODS: Forty six patients with focal pulmonary tumours who underwent preoperative computed tomographic (CT) and FDG-PET scanning were evaluated retrospectively. Thirty two patients had NSCLC and 14 patients had a benign process. The final diagnosis was established by means of histopathological examination at thoracotomy, and the nodal classification in patients with lung cancer was performed by thorough dissection of the mediastinal nodes at surgery.
RESULTS: FDG-PET was 80% sensitive, 100% specific, and 87.5% accurate in staging thoracic lymph nodes in patients with NSCLC, whereas CT scanning was 50% sensitive, 75% specific, and 59.4% accurate. The absence of lymph node tumour involvement was identified by FDG-PET in all 12 patients with NO disease compared with nine by CT scanning. Lymph node metastases were correctly detected by FDG-PET in three of five patients with N1 disease compared with two by CT scanning, in nine of 11 with N2 disease compared with six by CT scanning, an in all four with N3 nodes compared with two by CT scanning.
CONCLUSIONS: FDG-PET provides a new and effective method for staging thoracic lymph nodes in patients with lung cancer and is superior to CT scanning in the assessment of hilar and mediastinal nodal metastases. With regard to resectability, FDG-PET could differentiate reliably between patients with N1/N2 disease and those with unresectable N3 disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176535      PMCID: PMC1758560          DOI: 10.1136/thx.52.5.438

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  N C Gupta; A R Frank; N A Dewan; L S Redepenning; M L Rothberg; J A Mailliard; J J Phalen; J J Sunderland; M P Frick
Journal:  Radiology       Date:  1992-08       Impact factor: 11.105

Review 2.  Surgical treatment of lung cancer.

Authors:  M S Bains
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

Review 3.  Staging non-small cell lung cancer.

Authors:  P Armstrong; J M Vincent
Journal:  Clin Radiol       Date:  1993-07       Impact factor: 2.350

4.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer.

Authors:  T Naruke; K Suemasu; S Ishikawa
Journal:  J Thorac Cardiovasc Surg       Date:  1978-12       Impact factor: 5.209

5.  Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging.

Authors:  K M Kerr; D Lamb; C G Wathen; W S Walker; N J Douglas
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

6.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group.

Authors:  W R Webb; C Gatsonis; E A Zerhouni; R T Heelan; G M Glazer; I R Francis; B J McNeil
Journal:  Radiology       Date:  1991-03       Impact factor: 11.105

7.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.

Authors:  E F Patz; V J Lowe; J M Hoffman; S S Paine; P Burrowes; R E Coleman; P C Goodman
Journal:  Radiology       Date:  1993-08       Impact factor: 11.105

8.  Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.

Authors:  S D Rege; C K Hoh; J A Glaspy; D R Aberle; M Dahlbom; M K Razavi; M E Phelps; R A Hawkins
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

9.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.

Authors:  T C McLoud; P M Bourgouin; R W Greenberg; J P Kosiuk; P A Templeton; J A Shepard; E H Moore; J C Wain; D J Mathisen; H C Grillo
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

10.  Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).

Authors:  F G Duhaylongsod; V J Lowe; E F Patz; A L Vaughn; R E Coleman; W G Wolfe
Journal:  J Thorac Cardiovasc Surg       Date:  1995-07       Impact factor: 5.209

View more
  7 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

3.  [Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules].

Authors:  K Orino; M Kawamura; J Hatazawa; I Suzuki; Y Sazawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

4.  Morphometric analysis of regional lymph nodes in surgically resected non-small cell lung cancer.

Authors:  Hajimu Gotoh; Naoki Kanomata; Masahiro Yoshimura; Yoshiharu Ohno; Takuya Moriya; Chiho Ohbayashi
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

5.  Diagnostic value of EBUS-TBNA for lung cancer with non-enlarged lymph nodes: a study in a tuberculosis-endemic country.

Authors:  Chih-Hsi Kuo; Hao-Cheng Chen; Fu-Tsai Chung; Yu-Lun Lo; Kang-Yun Lee; Chih-Wei Wang; Wen-Han Kuo; Tzu-Chen Yen; Han-Pin Kuo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

6.  Positron emission tomography for staging of oesophageal and gastroesophageal malignancy.

Authors:  A C Kole; J T Plukker; O E Nieweg; W Vaalburg
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

7.  Surgical management of lung cancer.

Authors:  J E Dussek
Journal:  Cancer Imaging       Date:  2000-10-10       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.